Uncategorized

The company disclosed the appointment João Seabra the day before cutting its full-year sales outlook in response to continued challenges at its diagnostics division.

Supernus Pharmaceuticals and Indivior Pharmaceuticals are outlining a combined expected $2.2 billion in annual revenue, plus $125 million in cost savings that will include “natural redundancies.”

The COVID-19 pandemic heightened vaccine skepticism. Six years later, CVS’ chief medical officer talks about building trust with patients — and the surprising benefits of many vaccines.

BioNTech’s leadership transition was announced earlier this year, with CEO Ugur Sahin and CMO Özlem Türeci leaving to start a new mRNA company. Guido Oelkers of Swedish Orphan Biovitrum AB will take over as CEO in early 2027.

The hack is unlikely to affect Amgen’s financial reporting and other operations, nor does the pharma expect its ability to meet patient needs will be compromised.

If AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.

Novo Nordisk was banking on the inflammatory benefits of its investigational therapy ziltivekimab to improve cardiovascular outcomes. Last week’s Phase 3 failure dashed not just the Danish pharma’s hopes but that of other drugmakers working on the same pathway.

A mediados del siglo XX, la comunidad científica internacional estaba convencida de que el genoma era una estructura rígida, un conjunto de instrucciones estáticas alineadas de forma inmutable en los cromosomas. Sin embargo, una mujer armada únicamente con un microscopio, …

88% of IDR disputes go to providers. See how health plans can fix OON claims first.

Healthcare leaders must modernize their digital foundations to scale AI investments for long-term success.